WESPAC Advisors’s Gilead Sciences GILD Stock Holding History

WESPAC Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.01M	Buy	7,269 +940	+15%	+$132K	0.55%	53
2025 Q4	$777K	Buy	+6,329	New	+$769K	0.42%	75
2025 Q3	–	Sell	-9,495	Closed	-$1.05M	–	192
2025 Q2	$1.05M	Buy	9,495 +7,248	+323%	+$771K	0.74%	42
2025 Q1	$252K	Buy	+2,247	New	+$232K	0.21%	136
2024 Q2	–	Sell	-2,885	Closed	-$211K	–	161
2024 Q1	$211K	Sell	2,885 -44	-2%	-$3.38K	0.12%	157
2023 Q4	$237K	Buy	2,929 +1	+0%	+$78	0.16%	133
2023 Q3	$219K	Buy	+2,928	New	+$225K	0.16%	130
2016 Q2	–	Sell	-15,112	Closed	-$1.39M	–	111
2016 Q1	$1.39M	Buy	+15,112	New	+$1.36M	1.73%	15
2014 Q2	–	Sell	-14,190	Closed	-$1.01M	–	119
2014 Q1	$1.01M	Buy	14,190 +1,692	+14%	+$133K	0.87%	37
2013 Q4	$939K	Buy	12,498 +6,191	+98%	+$431K	0.78%	50
2013 Q3	$397K	Buy	+6,307	New	+$377K	0.46%	80

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

WESPAC Advisors's GILD Position: Q1 2026 in Review

WESPAC Advisors increased its Gilead Sciences (GILD) stake by 15% in Q1 2026, buying an estimated $132K and bringing the position to 7,269 shares worth $1.01M. The position accounts for 0.55% of the portfolio, ranked #53.

WESPAC Advisors first reported a position in GILD in Q3 2013 and has held it in 11 quarters since. The position peaked at $1.39M in Q1 2016. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

WESPAC Advisors held 7,269 shares of Gilead Sciences worth $1.01M as of Q1 2026.
WESPAC Advisors bought 940 Gilead Sciences shares in Q1 2026, an estimated $132K.
Gilead Sciences made up 0.55% of WESPAC Advisors's portfolio in Q1 2026, its #53 holding.
WESPAC Advisors first reported a position in Gilead Sciences in Q3 2013 and has held it in 11 quarters since.
WESPAC Advisors's Gilead Sciences position peaked at $1.39M in Q1 2016.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on WESPAC Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.